Last Updated: October 3, 2025
Analyzing Management
For hedge funds and asset managers, evaluating public company leadership plays a crucial role in both preliminary due diligence and continuous risk assessment. ManagementTrack offers a consistent methodology that eliminates distractions—highlighting strengths and weaknesses, identifying warning signs and positive indicators, and establishing a clear connection between CEO actions and financial performance.
CEO Koremans’ poor record on defense and finance casts doubt on launch execution.
Analysis of Recordati CEO Robert Koremans
With a history of failing to defend against generics and manage financial pressures, and mixed execution in rare diseases, Robert Koremans appears ill-suited for Recordati’s critical defensive and launch needs.
Management evaluated Robert Koremans’s track record and skillset against the following key factors for REC-IT:
- Navigating US tariff and BIOSECURE Act supply chain risks.
- Defending SPC cash flow against generic erosion.
- Defending margins against investment, FX, and debt pressures.
- Executing the critical H2 rare disease revenue ramp-up.
Robert Koremans’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
Faced with defending critical cash-flow products from generic erosion, does Koremans’s drive for commercial success override his discipline for legal and reputational risk management, as was alleged at Teva?
Question #2
When Koremans’s own debt-fueled M&A strategy creates significant margin pressure, does he demonstrate the operational discipline to protect profitability, or does he struggle to translate his strategic vision into execution under pressure as he did at Nutreco?
Question #3
Given the recent failure of the Ledaga launch, does Koremans possess the hands-on commercial execution skills to ensure his large rare disease acquisitions deliver their promised organic growth, or is his primary strength in M&A deal-making rather than post-acquisition sales ramp-up?
Why Do Investors Use ManagementTrack?
Q: What is ManagementTrack’s assessment of Robert Koremans at REC-IT?
A: Through proprietary career analysis and interviews with former colleagues, ManagementTrack establishes an executive’s track record, identifying key strengths and weaknesses. This profile is then evaluated against REC-IT’s most critical challenges, including navigating US supply chain risks from tariffs and the BIOSECURE Act, defending cash flow from generic competition, protecting margins from various financial pressures, and executing a crucial revenue increase for its rare disease portfolio.
Q: What additional tools does ManagementTrack employ to forecast company performance based on executive actions?
A: ManagementTrack utilizes proprietary models that identify unusual instances of executive evasion during earnings call Q&A sessions. It also performs a comprehensive analysis of insider transactions to pinpoint outlier trades that may predict future stock movements. These signals are integrated with the ManagementTrack Rating—a predictive 1-10 score for each executive—to provide investors with a distinct, forward-looking perspective on how management is likely to influence company results.
Q: Which companies and executives does ManagementTrack cover?
A: ManagementTrack provides real-time coverage of the c-suite for all publicly traded companies.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Author: Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Robert Koremans
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Recordati SpA 10Q
- Recordati SpA 10K
- Recordati SpA Earnings Calls
- Recordati SpA Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
